Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Health Care Resource Utilization, Cost and Other Outcomes of Patients Diagnosed With COPD Initiating Tiotropium Bromide/Olodaterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol

NCT05127304 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05127304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05127304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Health Care Resource Utilization, Cost and Other Outcomes of Patients Diagnosed With COPD Initiating Tiotropium Bromide/Olodaterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
February 26, 2021
Completion date
February 3, 2022
Enrollment
11,316 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive